AU2003259358A1 - Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use - Google Patents

Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Info

Publication number
AU2003259358A1
AU2003259358A1 AU2003259358A AU2003259358A AU2003259358A1 AU 2003259358 A1 AU2003259358 A1 AU 2003259358A1 AU 2003259358 A AU2003259358 A AU 2003259358A AU 2003259358 A AU2003259358 A AU 2003259358A AU 2003259358 A1 AU2003259358 A1 AU 2003259358A1
Authority
AU
Australia
Prior art keywords
immunogenic composition
therapeutic use
cell epitopes
epitopes
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259358A
Other languages
English (en)
Other versions
AU2003259358A8 (en
Inventor
Claire Ashman
Jonathan Henry Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220212A external-priority patent/GB0220212D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003259358A8 publication Critical patent/AU2003259358A8/xx
Publication of AU2003259358A1 publication Critical patent/AU2003259358A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003259358A 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use Abandoned AU2003259358A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0220212A GB0220212D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0220212.5 2002-08-30
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
GB0304672.9 2003-02-28
PCT/GB2003/003703 WO2004019974A2 (en) 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Publications (2)

Publication Number Publication Date
AU2003259358A8 AU2003259358A8 (en) 2004-03-19
AU2003259358A1 true AU2003259358A1 (en) 2004-03-19

Family

ID=31980003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259358A Abandoned AU2003259358A1 (en) 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Country Status (8)

Country Link
US (1) US20060147417A1 (enExample)
EP (1) EP1532172A2 (enExample)
JP (1) JP2006503017A (enExample)
AR (1) AR041086A1 (enExample)
AU (1) AU2003259358A1 (enExample)
CA (1) CA2496409A1 (enExample)
TW (1) TW200407162A (enExample)
WO (1) WO2004019974A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
MX2009003188A (es) * 2006-09-25 2009-05-22 Sj Biomedic Inc Polipeptidos hibridos inmunogenicos antiobesidad y composicion de vacuna antiobesidad que comprende los mismos.
AU2010269120B2 (en) * 2009-07-06 2015-09-24 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
WO2015017034A1 (en) * 2013-08-02 2015-02-05 Gourdie Robert G Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
MX2021007906A (es) 2018-12-28 2021-10-13 United Biomedical Inc Nmunógenos peptídicos dirigidos a la interleucina 6 (il-6) y sus formulaciones para la inmunoterapia de enfermedades afectadas por la desregulación de la il-6.
WO2022114810A1 (ko) * 2020-11-26 2022-06-02 재단법인 아산사회복지재단 프로그래뉼린 단백질 또는 이의 활성 단편을 유효성분으로 포함하는 섬유화 질환 예방 또는 치료용 약학 조성물
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance
CA3229324A1 (en) * 2021-08-20 2023-02-23 Beatrice DROUET Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EE200100552A (et) * 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens

Also Published As

Publication number Publication date
WO2004019974A3 (en) 2004-07-22
WO2004019974A2 (en) 2004-03-11
EP1532172A2 (en) 2005-05-25
CA2496409A1 (en) 2004-03-11
TW200407162A (en) 2004-05-16
AU2003259358A8 (en) 2004-03-19
AR041086A1 (es) 2005-04-27
JP2006503017A (ja) 2006-01-26
US20060147417A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
GB0212885D0 (en) Therapeutic epitopes and uses thereof
AU2003259358A8 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
IL201916A (en) Stem cells from human placenta, their characteristics, preparation and use
ZA200709266B (en) Human GLP-1 mimetibodies, compositions, methods and uses
AU2003243984A1 (en) Hydrogenated copolymer and composition thereof
AU2003237788A1 (en) Electrode constructs, and related cells and methods
AU2003239614A1 (en) Cardiolipin compositions, methods of preparation and use
AU2003213421A1 (en) Heat storing material, composition thereof and their use
FR2849381B1 (fr) Composition cosmetique, solaire et bio-bronzante
TWI319400B (en) Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application
AU2003224747A1 (en) Technetium-labeled rotenone derivatives, and methods of use thereof
DE60237654D1 (de) Komplexes Lithium-Mangan-Oxid, dessen Herstellung und Verwendung
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
AU2003246130A1 (en) Heat-storage material, composition therefor, and uses of these
AU2003224313A1 (en) Mycobacterial antigens and uses thereof
AU2003259374A1 (en) Vaccine comprising il-13 and an adjuvant
PL371382A1 (en) Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
GB2409796B (en) Composition comprising proteinaceous material, its preparation and use
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
GB0317376D0 (en) Immunogenic protein and uses thereof
AU2002315931A1 (en) Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use
AU2003282980A1 (en) 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase